Stelios Papadopoulos, Director at Regulus Therapeutics Inc. (RGLS), bought 100,000 shares at $1.09 ($109K) on 2018-12-28, disclosed to the SEC on 2019-01-02.
Open-market purchase of $109k RGLS by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.09 | 50,000 | $55K | 50.0% |
| 2 | $1.09 | 50,000 | $55K | 50.0% |
| Total | $1.09 avg | 100,000 | $109K | 100% |
| Filing → |
| EXEL | SELL | 2024-05-22 | $240K | — | Filing → |
| EXEL | SELL | 2022-02-24 | $3.3M | — | Filing → |
| EXEL | SELL | 2021-05-13 | $911K | — | Filing → |